Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2012 5
2013 7
2014 2
2015 2
2016 4
2017 4
2018 7
2019 3
2020 3
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Emerging drugs for non-alcoholic steatohepatitis.
Tomeno W, Yoneda M, Imajo K, Ogawa Y, Kessoku T, Saito S, Eguchi Y, Nakajima A. Tomeno W, et al. Expert Opin Emerg Drugs. 2013 Sep;18(3):279-90. doi: 10.1517/14728214.2013.811232. Epub 2013 Jul 13. Expert Opin Emerg Drugs. 2013. PMID: 23848366 Review.
Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs.
Tomeno W, Imajo K, Takayanagi T, Ebisawa Y, Seita K, Takimoto T, Honda K, Kobayashi T, Nogami A, Kato T, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Sakamoto Y, Yoneda M, Saito S, Nakajima A. Tomeno W, et al. Diagnostics (Basel). 2020 Nov 7;10(11):912. doi: 10.3390/diagnostics10110912. Diagnostics (Basel). 2020. PMID: 33171865 Free PMC article. Review.
MRI-Based Quantitative R2* Mapping at 3 Tesla Reflects Hepatic Iron Overload and Pathogenesis in Nonalcoholic Fatty Liver Disease Patients.
Imajo K, Kessoku T, Honda Y, Hasegawa S, Tomeno W, Ogawa Y, Motosugi U, Saigusa Y, Yoneda M, Kirikoshi H, Yamanaka S, Utsunomiya D, Saito S, Nakajima A. Imajo K, et al. Among authors: tomeno w. J Magn Reson Imaging. 2022 Jan;55(1):111-125. doi: 10.1002/jmri.27810. Epub 2021 Jun 28. J Magn Reson Imaging. 2022. PMID: 34184822
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: tomeno w. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):996-1007. doi: 10.1016/S2468-1253(20)30216-8. Epub 2020 Aug 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32805205 Clinical Trial.
Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin.
Ogawa Y, Imajo K, Honda Y, Kessoku T, Tomeno W, Kato S, Fujita K, Yoneda M, Saito S, Saigusa Y, Hyogo H, Sumida Y, Itoh Y, Eguchi K, Yamanaka T, Wada K, Nakajima A. Ogawa Y, et al. Among authors: tomeno w. Sci Rep. 2018 Jul 27;8(1):11365. doi: 10.1038/s41598-018-29735-6. Sci Rep. 2018. PMID: 30054551 Free PMC article.
38 results